CXCR4-targeted PET/CT Imaging in Hematological Malignancies
Status:
Not yet recruiting
Trial end date:
2024-03-31
Target enrollment:
Participant gender:
Summary
The incidence and mortality of hematological malignancies remain high. Although 18F-FDG
PET/CT imaging is the most common molecular imaging technique used in clinic, the
non-specific uptake of 18F-FDG leads to the problems of false negative or positive in
hematological malignancies, which makes it difficult to diagnose and evaluate the efficacy.
CXCR4 (C-X-C Chemokine Receptor Type 4) is overexpressed in various hematological
malignancies, and is associated with poor prognosis. CXCR4-targeted molecular imaging, such
as 68Ga-pentixafor PET/CT imaging, has an important potential in hematological malignancies.
Therefore, this study will evaluate the efficacy of CXCR4-targeted PET/CT imaging for
diagnosis and staging of hematological malignancies, compared with 18F-FDG PET/CT imaging.